Answering Your Frequently Asked Questions
The 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for learning, networking, and partnering with key and emerging leaders in pain drug development.
Bringing together 150+ leaders from pharma, biotech, academia, and investment, the event explores the latest mechanisms, biomarkers, and development strategies shaping the future of pain therapeutics.
This summit is designed for senior decision-makers, with over 70% of attendees at the 2026 event representing C-suite, VP, and Director-level roles. This meeting brings together discovery scientists, translational leaders, clinical developers, business development executives, and investors to tackle the challenges holding the field back. From improving target and biomarker validation and patient stratification to placebo mitigation strategies, refining trial design, identifying investable assets, and learning from both successful and failed programs.
The conference will take place in Boston, Massachusetts, at the Hyatt Regency Boston Harbor, located at 101 Harborside Drive, Boston, MA 02128.
As a global hub for biotech and pharmaceutical innovation, Boston provides the ideal setting for collaboration, networking, and knowledge exchange among pain-focused and CNS drug development leaders.
You'll meet C-suite, VP, and Director-level roles, discovery scientists, translational leaders, clinical developers, business development executives, and investors. Attending and speaking organizations include Vertex Pharmaceuticals, Eli Lilly, AbbVie, 4E Therapeutics, Grünenthal, Xenon Pharmaceuticals, Levicept, NIH, and many more.
The agenda spans the full pain therapeutics landscape, with key themes including:
- Defining The Next Era Of Non-Opioid Pain Therapeutics
- Beyond NaV1.8 What Mechanisms Could Define the Next Generation of Pain Therapies
- Can We Finally Get Pain Trials Right? Bottlenecks in Clinical Development & How to Fix Them
- Refining NaV1.8 & GLP-1 as Revolutionary Mechanisms for Pain R&D
- Building Better Pain Medicines Through Novel Biology
- Deliver Durable Relief Through Gene Regulation? Learning From Adjacent Neuroscience Fields Spanning Epilepsy & Migraine
- Building the Future Commercial Pain Ecosystem
Unlike broader pain and neuroscience meetings, this summit is dedicated exclusively to the discovery, development, and commercialization of non-opioid pain therapeutics. Bringing together experts across pain biology, translational science, clinical development, business development, venture investment, and patient advocacy, it provides a unique forum to discuss the science, clinical strategies, and commercial realities shaping the future of pain medicine.
With dedicated Discovery & Preclinical and Translation & Clinical workshop tracks, attendees can tailor their pre-conference experience to the topics most relevant to their role, from novel target discovery and translational models to placebo mitigation, patient selection, and clinical trial optimization.
• Learn how leading organizations are advancing the next generation of non-opioid pain therapeutics across sodium channels, neuroimmune pathways, GLP-1 biology, neurotrophins, gene regulation, and beyond
• Gain insights into the latest clinical data, translational models, and target engagement strategies shaping pain drug development
• Discover new approaches to improving clinical success through better trial design, placebo mitigation, patient stratification, and biomarker development
• Benchmark discovery, translational, and clinical development strategies with peers across pharma, biotech, academia, and patient advocacy
• Build relationships with key decision-makers spanning R&D, clinical development, business development, venture investment, and commercial strategy
• Leave with practical insights to accelerate the discovery, development, and commercialization of next-generation pain medicines
You can register directly through the official summit website. Multiple pass options are available, including full-access and conference-only passes for drug developers, academics, and solution providers. Early booking discounts are available for qualifying registrations.
Partnering with the Non-Opioid Pain Therapeutics Summit gives you direct access to senior decision-makers who are actively evaluating technologies, services, and partnerships to accelerate the development of pain therapeutics.
Sponsorship opportunities allow you to showcase your expertise, generate new business opportunities, increase brand visibility, and position your organization as a trusted partner within the pain therapeutic community.
The summit takes place from January 26-28, 2027, in Boston, Massachusetts.
Pre-Conference Day (January 26):
4 Industry Focused Workshops:
- Translating Human Pain Biology Beyond Animal Models into Predictive Drug Development
- Optimizing Clinical Trial Design to Detect Efficacy & Mitigate High Placebo Response in Chronic Pain
- Discovering & Validating Novel Targets to Drug Ready Mechanisms for Non-Opioid Pain
- Target Failure or Trial Failure? Re-Evaluating Why Pain Programs Fail
Conference Days (January 27-28):
- Keynotes, technical presentations, panel discussions, and case studies from biopharma leaders
- Scientific poster sessions and networking opportunities
Yes. Group discounts are available for organizations registering multiple delegates.
Discounts apply when two or more delegates from the same company register and pay at the same time. Savings increase for larger groups, with discounts available for 3, 4, and 5+ passes.
Yes. Discounted academic rates are available for eligible academic and research attendees. Bookings are subject to approval and attendees should select the appropriate pricing category when registering.
For questions about registration, attendance, speaking opportunities or pricing:
Email: info@hansonwade.com
For sponsorship and partnership enquiries:
Email: sponsor@hansonwade.com
The team will be happy to assist with any questions relating to attendance, registration or partnership opportunities.